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Increased Arterial Stiffness is an Independent Predictor of Renal
Function Decline in Patients With Type 2 Diabetes Mellitus Younger
Than 60 Years
Nikolaos Fountoulakis, MD; Chiraag Thakrar, MBBS; Kishan Patel, MBBS; Giancarlo Viberti, MD, FRCP; Luigi Gnudi, MD, PhD;
Janaka Karalliedde, MRCP, PhD
Background-—The objective of this study was to evaluate whether aortic pulse wave velocity (Ao-PWV) predicts estimated
glomerular ﬁltration rate (eGFR) decline in patients with type 2 diabetes mellitus.
Methods and Results-—This prospective single-center cohort study investigated 211 type 2 diabetes mellitus patients with eGFR
≥45 mL/min with a baseline mean age of 60.1 years (range, 30–82 years). The meanSD baseline eGFR was 8526.1 mL/min.
We divided the cohort into 2 groups above (n=117, “older”) and below (n=94, “younger”) the mean age to evaluate whether
Ao-PWV predicted progression of kidney disease differentially in older and younger patients. The primary end point was reaching a
ﬁnal eGFR below the median for the age group and an eGFR fall ≥1 mL/min per year. Median follow-up was 9 years (range, 3–11
years) and 50% of patients in both groups reached the primary end point. In older patients, Ao-PWV was similar in those who did
and did not reach the primary end point. By contrast, younger patients who reached the primary end point had a higher Ao-PWV at
baseline compared with those who did not (10.8 m/s versus 9.5 m/s, respectively; mean difference of 1.36 m/s [95% CI,
0.38–2.33], P=0.007). Ao-PWV was an independent predictor of the primary end point (incident risk ratio, 1.09; 95% CI, 1.02–1.18)
after adjustment for traditional risk factors only in younger patients (P=0.02). A 1m/s increase in Ao-PWV was associated with a
mean fall in eGFR of 2.1 mL/min per year (95% CI, 0.09–4.1) independent of other risk factors in younger patients (P=0.04).
Conclusions-—Ao-PWV predicts eGFR decline, before the onset of advanced renal dysfunction, and is a potential target for
renoprotection in younger patients with type 2 diabetes mellitus. ( J Am Heart Assoc. 2017;6:e004934. DOI: 10.1161/JAHA.
116.004934.)
Key Words: aortic stiffness • arterial stiffness • diabetes (kidney) • renal disease progression • renal insufﬁciency • type 2
diabetes mellitus
I ncreased arterial stiffness, involving accelerated vascularaging of the aorta, is a powerful risk factor for early mortality
and progression of renal function decline as measured by
estimated glomerular ﬁltration rate (eGFR) in patients with
advanced stages of chronic kidney disease (CKD).1–3 Aortic
pulse wave velocity (Ao-PWV) is the most reliable measure of
arterial stiffness that predicts cardiorenal outcomes.4 Increased
Ao-PWV leads to greater transmission of pressure changes to
the renal microcirculation with the resultant exposure of
glomerular capillaries to damaging pulsatile pressures.2 Both
the kidney and the brain have high volume ﬂow at very low
vascular resistance and are therefore exquisitely vulnerable to
pressure-induced damage.5,6 We previously demonstrated an
inverse relationship of Ao-PWV with eGFR in type 2 diabetes
mellitus (T2DM) patients with comparatively preserved renal
function, suggesting that even modest renal functional impair-
ment is associated with changes in the elastic properties of the
aorta well before the onset of overt renal insufﬁciency.7 The
predictive role of Ao-PWV on eGFR decline in T2DM patients
with eGFR >45 mL/min is unclear.
Therefore, we evaluated whether Ao-PWV predicted eGFR
decline in a prospective observational single-center cohort
study of 211 T2DM patients with relatively preserved renal
function.
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Research Design and Methods
This was a prospective cohort study of T2DM patients with
eGFR ≥45 mL/min attending the diabetes clinic at Guy’s
Hospital, London, UK, between 2002 and 2004 for baseline
measurements. All patients were followed to 2015 or their
death, a median time interval of 9 years (range, 3–11 years).
T2DM was deﬁned according to American Diabetes Associ-
ation criteria.8 Exclusion criteria were presence of connective
tissue diseases known to affect arterial vasculature, history of
nondiabetic kidney disease, and pregnancy.
All baseline measurements and procedures were taken
with the patients in the fasted state and having refrained
from nicotine, alcohol, and caffeine for at least the previous
10 hours. Brachial blood pressure (BP) was measured in
triplicate in the supine position with an automated sphyg-
momanometer (Omron Digital Blood Pressure Monitor
HEM907, Bannockburn, IL). Ao-PWV was determined from
carotid and femoral pressure waveforms obtained noninva-
sively by applanation tonometry (Millar Instruments, Hous-
ton, TX) using the Sphygmocor system (AtCor Medical,
Sydney, Australia) as previously described.7 The distance
between the surface markings of the sternal notch and the
carotid (dc) and femoral artery (df) were used to estimate
the path length between the carotid and femoral arteries
(L=dfdc) and Ao-PWV computed as L/DT.7 The within-
subject SD of Ao-PWV assessed using this method in our
laboratory is 0.5 m/s. The intraobserver coefﬁcient of
variation was 3.5%.7,9
Standardized clinical and biochemical measures were
performed at least annually for the duration of the follow-up
period. These included urine albumin to creatinine ratio (ACR)
from morning urine samples (urine creatinine [by Jaffe
reaction] and urine albumin concentration [by immunotur-
bidimetry]) determined using a Cobas Mira Plus analyzer
(Roche Diagnostics, Basel, Switzerland), serum total choles-
terol (enzymatic colorimetry), and serum creatinine (Jaffe rate
reaction method) using a Cobas Mira Plus analyzer (Roche
Diagnostics).7 Glycated hemoglobin (HbA1c) was measured by
boronate afﬁnity high-pressure liquid chromatography (Primus
CLC330, Kansas City, MO).
Arterial hypertension was diagnosed if mean systolic BP
was >140 mm Hg or diastolic BP was >90 mm Hg or if the
patient was taking antihypertensive drugs. Ischemic cardio-
vascular disease, cerebrovascular disease, peripheral vascular
disease, and medication history were conﬁrmed from clinical
records. Diabetic retinopathy was evaluated from a diabetic
retinal screening database and the clinical records of the
ophthalmology department.
eGFR was determined using the Chronic Kidney Disease
Epidemiology Collaboration Formula equation.10 The natural
rate of glomerular ﬁltration rate (GFR) decline with age as
described in longitudinal studies is up to 1 mL/min per
year,11,12 and this decline commences in patients aged 30 to
40 years.11 An acceleration in the rate of decline of GFR is
described after the age of 60 years.11
Many patients with T2DM do not have signiﬁcant progres-
sion of renal impairment. In a recent study in T2DM patients
with eGFR >60 mL/min, 85% of the cohort had an annual
decline in GFR <1 mL/min.13 In T2DM patients with a
baseline eGFR <60 mL/min, the annual decline of renal
function was 0.85 mL/min.14
For these reasons, we based the deﬁnition of progression
in our cohort with early kidney disease as a fall in eGFR
≥1 mL/min per year. We ﬁrst evaluated whether the baseline
Ao-PWV predicted eGFR decline across the whole cohort, as
our previous cross-sectional data suggested an inverse
relationship between Ao-PWV and eGFR. Because age is the
most powerful determinant of Ao-PWV and also determines
the natural rate of eGFR decline, it could potentially confound
the relationship between Ao-PWV and progression of renal
dysfunction. To address this, we divided the cohort into 2
groups above and below the mean age of the cohort
(60 years). The median eGFR at the end of follow-up in each
age group was used to categorize those patients with
progression of renal dysfunction to obtain a more precise
age and cohort-speciﬁc cutoffs for progression of renal
dysfunction in this population.
Patients with ﬁnal eGFR below the median for the group
and annual fall in GFR ≥1 mL/min were deﬁned as progres-
sors and those with ﬁnal eGFR above the median and annual
fall in GFR <1 mL/min were deﬁned as nonprogressors. We
also evaluated eGFR change as a continuous factor in a
repeated measures mixed model analysis.
The study was approved by the research ethics committee
of Guy’s and St. Thomas’s Hospitals. All patients gave
informed consent and the study was undertaken in adherence
to the Declaration of Helsinki.
Statistical Analysis
Descriptive statistics were used for the analysis of demo-
graphic and clinical features of the cohort. ACR values were
log-transformed before calculation because of their positively
skewed distribution. Patients with and without progression of
kidney disease were compared by unpaired t test (for
continuous normal variables), Mann–Whitney test (for contin-
uous nonparametrically distributed variables), and chi-square
test (for categorical variables). Differences signiﬁcant at the
<10% level were entered in a Poisson (log-linear) multiple
regression model with progression of kidney disease as the
dependent variable to determine which variables best pre-
dicted progression. For each patient, a linear regression
model of time on eGFR (least-squares method) was created,
DOI: 10.1161/JAHA.116.004934 Journal of the American Heart Association 2
Aortic Stiffness Predicts Early GFR Decline Fountoulakis et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on M
ay 24, 2017
http://jaha.ahajournals.org/
D
ow
nloaded from
 
and the slope of the regression line was used to estimate the
patient’s changes in eGFR over time.15
Candidate variables entered into the multivariate regres-
sion models included the following: age, sex, diabetes mellitus
duration, smoking status, hypertension, antihypertensive
treatment, (number and classes of drugs), pulse pressure,
mean arterial pressure, systolic BP, retinopathy status, ACR,
HbA1c, baseline eGFR, and number of eGFR measurements.
Three investigators, who were blinded to baseline Ao-PWV
results, independently collected all of the follow-up data. Data
are given as meanSD or 95% CIs, percentage for categorical
variables, or median and interquartile range for variables not
normally distributed. Poisson regression results are presented
as incident rate ratios, calculated as the exponential of the
estimated regression coefﬁcients, with their respective 95%
CIs, and a 2-tailed P<0.05 was considered signiﬁcant. Poisson
multivariate regression analyses is suitable when analyzing
time to event data and when times between successive
events are independent and exponentially distributed (as in
our data set).
This approach also allows dependence of risk on multiple
time scales and enables for direct estimation of the survival
distribution function and estimation of relative risks.16,17
To evaluate the variables that predicted longitudinal
change in eGFR during follow-up, a repeated measures linear
mixed model (with random intercepts and slopes speciﬁc to
each participant) were used.18–20 Regression diagnostics
(omnibus test and change in maximum likelihood) were
examined and these indicated no signiﬁcant overspeciﬁcation.
Collinearity diagnostics (variance inﬂation factor and toler-
ance) were examined and excluded signiﬁcant collinearity.
We also performed net reclassiﬁcation improvement21,22
analyses to determine improvement in risk prediction when
Ao-PWV was added to traditional predictors of renal disease
progression with MATLAB 2014a software (MathWorks,
Natick, MA). All other statistical analyses were performed
with SPSS version 19.0 (SPSS Inc, Chicago, IL).
Results
The baseline demographic and clinical characteristics of the
whole cohort (n=211) and in those “older” (above mean age
n=117) and “younger” (below mean age n=94) is shown in
Table 1.
In the whole cohort, there were 136 men and 75 women
with a mean age (range) of 60.1 (30–82) years. Approximately
56% of patients were of Caucasian origin, 10% of Asian origin,
and 34% of Afro-Caribbean origin. Forty-six percent of patients
had never smoked and 77% were taking treatment with
inhibitors of the renin-angiotensin-aldosterone system.
Approximately 73% were taking oral antidiabetic agents and
27% insulin treatment for diabetes mellitus. A conﬁrmed
Table 1. Baseline Demographic, Clinical and Biochemical Characteristics of the Whole Cohort of 211 Patients and of Those Below
(“Younger”) and Above (“Older”) Mean Age of Cohort
Whole Cohort (N=211) Younger (n=94) Older (n=117)
P Value
Younger vs Older
Age, y* 60.1 (33–82) 50.5 (33–59) 67.5 (60–82)
Male sex, % 64 66 62 0.44
Diabetes mellitus duration, years 9.96.7 7.74.7 11.87.6 <0.001
Hypertension, % 88 86 90 0.32
Body mass index, kg/m2 31.86.2 33.17.2 30.75.1 0.005
SBP, mm Hg 141.916.6 139.715.0 143.017.8 0.16
DBP, mm Hg 79.68.8 82.28.9 77.48.3 <0.001
Mean arterial pressure, mm Hg 98.713.3 99.512.0 98.013.0 0.4
Pulse pressure, mm Hg 62.114.2 57.612.2 65.914.8 <0.001
Urine ACR, mg/mmol† 2.5 (0.8–8.8) 3.65 (0.8–11.7) 2.25 (0.8–6.77) 0.54
Total cholesterol, mmol/L 4.470.86 4.440.78 4.50.8 0.60
Glycated hemoglobin, % 7.81.4 7.81.3 7.81.4 0.9
Estimated GFR, mL/min 85.326.1 97.523.1 73.223 <0.001
Ao-PWV, m/s 11.12.7 10.12.3 12.042.7 <0.001
Values are expressed as meanSD unless otherwise stated. ACR indicates albumin to creatinine ratio; Ao-PWV, aortic pulse wave velocity; DBP, diastolic blood pressure; GFR, estimated
glomerular ﬁltration rate; SBP, systolic blood pressure.
*Values expressed as mean (range).
†Values expressed as median (interquartile range).
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diagnosis of diabetic retinopathy was present in 47% of
patients and 5% had a history of cardiovascular disease at
baseline. At baseline 49% of patients were normoalbuminuric
(ACR <3 mg/mmol), 37% had microalbuminuria (ACR 3–
30 mg/mmol), and 14% had ACR >30 mg/mmol.
In the whole cohort of 211 patients, baseline Ao-PWV was
not signiﬁcantly different between patients with progression
of renal dysfunction versus those with no progression
(11.22.6 versus 10.82.6 [P=0.28], respectively). Progres-
sors were signiﬁcantly older (61.69.6 years versus
58.510.8 years, P=0.03), had higher urine ACR (median
3.8 [interquartile range, 0.87–18.2] versus 2.3 [0.7–4.8] mg/
mmol; P=0.001), and lower baseline eGFR (7220 mL/min
versus 9223 mL/min, P=0.001). Approximately 66% of the
cohort had an Ao-PWV ≥10 m/s. Patients with an Ao-PWV
above this cutoff did not have higher risk of progression of
renal dysfunction when compared with patients below it. We
observed a signiﬁcant inverse association between baseline
eGFR and Ao-PWV in the whole cohort similar to what we and
others have previously described.7
Because eGFR, Ao-PWV, and age are statistically and
biologically highly interrelated and correlated, to investigate
whether age may have confounded the relationships between
Ao-PWV and progression, we divided the cohort into 2 age
groups above (“older”) and below (“younger”) the mean age of
the cohort, at baseline. Older patients had signiﬁcantly longer
duration of diabetes mellitus; lower body mass index, eGFR,
and diastolic BP; and higher pulse pressure and Ao-PWV at
baseline (Table 1, P<0.05 for all). The effect of age within
both subgroups was linear.
After a median time interval of 9 years (range 3–11), 49%
of younger and 50% of older patients had progression. The
baseline characteristics of patients with and without progres-
sion in each age category are shown in Table 2 (older
patients) and Table 3 (younger patients), respectively.
Older patients with progression had signiﬁcantly higher
body mass index, higher urine ACR, and a lower baseline eGFR
compared with those without progression (P<0.05 for all;
Table 2). Ao-PWV was similar in older patients with
(12.032.7 m/s) and without (12.022.6 m/s) progression
(Figure) and not signiﬁcantly associated with progression of
renal dysfunction.
The proportion of Ao-PWV ≥10 m/s in younger patients
was 51% and in older patients was 78%. Patients with an
Ao-PWV above this cutoff did not have a higher risk of
progression of renal dysfunction when compared with
patients below it in either age group.
Younger patients with progression had a signiﬁcantly longer
duration of diabetes mellitus; higher prevalence of hyperten-
sion, higher systolic BP, and urine ACR; and a lower eGFR at
baseline (P<0.05 for all; Table 3) compared with patients
without progression. Progressors had a mean annual fall in
eGFR of 3.85 mL/min per year (95% CI, 4.58 to 3.18)
compared with 0.7 mL/min per year (95% CI, 0.33–1.01) in
nonprogressors and a ﬁnal eGFR <83 mL/min (median eGFR at
end of follow-up for the age group). In patients with progression,
meanSD baseline and ﬁnal eGFR was 87.015.5 and
57.020.6 mL/min, respectively, compared with 98.515
and 102.611.6 mL/min in nonprogressors.
In younger patients, meanSD Ao-PWV was signiﬁcantly
higher in patients with progression of renal function decline
(10.82.6 m/s) compared with patients without progression
(9.52.0 m/s), a mean 95% CI difference of 1.36 m/s (0.38–
2.33) (P=0.007; Figure A). Ao-PWV was signiﬁcantly associ-
ated with age, ACR, and pulse pressure in bivariate analyses.
There were no signiﬁcant differences in age, sex, ethnicity
including proportion of patients of Afro-Caribbean ethnicity,
smoking status, body mass index, HbA1c, prevalence of
retinopathy, drug treatments (including use of renin-angio-
tensin-aldosterone system inhibitors), peripheral vascular
disease, or cardiovascular disease in patients who had
progression compared with those with no progression.
Table 2. Comparison of Baseline Characteristics of 117
Older T2DM Patients With or Without Progression of Renal
Dysfunction
Progressors
(n=59)
Nonprogressors
(n=58) P Value
Age, y 68.14.8 67.24.7 0.3
Male sex, % 60 66 0.54
Diabetes mellitus
duration, y
11.56.8 128.2 0.7
Hypertension, % 95 86.5 0.5
RAAS inhibitor
treatment, %
80.4 78.3 0.79
Body mass index,
kg/m2
31.85.5 29.54.4 0.016
SBP, mm Hg 144.616.6 142.718.6 0.69
DBP, mm Hg 77.27.7 77.88.8 0.57
Pulse pressure,
mm Hg
67.114.4 64.815.2 0.4
Urine ACR, mg/mmol* 4.05 (0.8–20.4) 1.5 (0.77–4.4) 0.006
Cholesterol, mmol/L 4.40.8 4.50.7 0.32
Glycated hemoglobin, % 7.831.6 7.861.2 0.92
Baseline eGFR, mL/min 62.215.1 86.523.5 <0.001
Final eGFR, mL/min 42.216.3 84.513.6 <0.001
Ao-PWV, m/s 12.032.7 12.022.6 0.99
Values are expressed as meanSD unless otherwise stated. ACR indicates albumin to
creatinine ratio; Ao-PWV, aortic pulse wave velocity; DBP, diastolic blood pressure; eGFR,
estimated glomerular ﬁltration rate; RAAS, renin-angiotensin-aldosterone system; SBP,
systolic blood pressure.
*Values expressed as median (interquartile range).
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In younger patients, baseline Ao-PWV was a predictor of
progression with an increased incident risk ratio of 1.09 (95%
CI, 1.02–1.18; P=0.02) independent of traditional risk factors
such as age (baseline and ﬁnal when entered either together
or individually to the model), sex, mean arterial pressure or
systolic BP or pulse pressure, hypertension or number of
antihypertensive agents, baseline eGFR, duration of diabetes
mellitus, total cholesterol, HbA1c, number of eGFR measure-
ments, and ACR.
Table 4 presents the independent variables that predicted
the progression by Poisson regression in younger patients.
This model suggests that an increase in Ao-PWV of 1 m/s
Table 3. Comparison of Baseline Characteristics of 94 Younger T2DM Patients With or Without Progression of Renal Dysfunction
Progressors (n=46) Nonprogressors (n=48) P Value
Age, y 51.66.2 49.56.5 0.12
Male sex, % 67 58 0.43
Diabetes mellitus duration, y 8.95.6 6.93.8 0.05
Hypertension, % 94 75 0.01
RAAS inhibitor treatment, % 80 60 0.17
Body mass index, kg/m2 33.75.6 33.78.7 0.97
SBP, mm Hg 143.314.2 136.215.1 0.02
DBP, mm Hg 82.57.6 79.89.2 0.13
Mean arterial pressure, mm Hg 102.78 98.710.1 0.04
Pulse pressure, mm Hg 60.713.5 56.511 0.09
Urine ACR, mg/mmol* 5.35 (1.22–19.8) 2.35 (0.47–5.77) 0.007
Cholesterol, mmol/L 4.70.76 4.320.86 0.15
Glycated hemoglobin, % 7.81.27 7.71.44 0.64
Baseline eGFR, mL/min 87.015.6 98.515.1 0.001
Final eGFR, mL/min 57.020.6 102.611.6 0.001
Ao-PWV, m/s 10.82.6 9.52.0 0.007
Values are expressed as meanSD unless otherwise stated. ACR indicates albumin to creatinine ratio; Ao-PWV, aortic pulse wave velocity; eGFR, estimated glomerular ﬁltration rate; RAAS,
renin-angiotensin-aldosterone system.
*Values expressed as median (interquartile range).
n=46                                   n=48 n=59                                             n=58
A BYounger T2DM Older T2DM
Figure. Ao-PWV in 211 T2DM “younger” (A) and “older” (B) patients with or without progression of renal
function decline. Ao-PWV indicates aortic pulse wave velocity; T2DM, type 2 diabetes mellitus.
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increased the risk of progression of renal function decline by
9% independent of traditional risk factors/predictors. The
unadjusted and adjusted effect of Ao-PWV on progression of
renal disease is reported in Table 5. The results from an
unadjusted model and a model adjusted for age, sex, and
baseline eGFR indicates that a 1-m/s increase in Ao-PWV
increases risk of progression by 12%.
The only other independent variable that signiﬁcantly
predicted progression was a lower baseline eGFR (incident
risk ratio, 0.98; 95% CI, 0.97–0.99 [P=0.002]). Baseline
albuminuria (incident risk ratio, 1.06; 95% CI, 0.95–1.17
[P=0.288]) increased the risk of progression but this did not
reach statistical signiﬁcance. Similarly, when ACR was entered
as a categorical (microalbuminuria and macroalbuminuria) risk
marker, it did not signiﬁcantly predict progression.
We examined the relationship between baseline eGFR
and progression of renal dysfunction and, as would be
expected, a lower baseline eGFR predicted faster rate of
eGFR fall. Patients with a 1-mL/min lower baseline eGFR
had a greater mean reduction in eGFR of 0.84 (95% CI,
0.57–1.10) and 0.9 (95% CI, 0.76–1.04) mL/min per year in
younger and older patient groups, respectively. Similarly,
younger and older patients with a 1-mL/min lower baseline
eGFR had a 2% and 3% higher incident risk ratio of
progression, respectively.
In a linear mixed model analysis, a 1-m/s increase in
Ao-PWV was associated with a mean fall in eGFR independent
of other established risk factors (2.1; 95% CI, 0.09–4.1 mL/
min per year [P=0.04]) only in younger patients (Table 6).
We also performed net reclassiﬁcation improvement
analyses to determine improvement in risk prediction when
Ao-PWV was added to traditional predictors of renal disease
progression. The net reclassiﬁcation improvement analyses
demonstrated that including Ao-PWV in the model correctly
reclassiﬁed a further 9% of the “young” progressors
compared with a model without Ao-PWV. In brief, 4 patients
of a total 46 progressors (P=0.04) and 1 of 48 nonprogressors
(P=0.3) were correctly reclassiﬁed with an overall statistically
signiﬁcant net reclassiﬁcation improvement of 0.11 (P=0.02).
Table 4. Results of Poisson Regression Analysis for Baseline
Variables That Predict Progression Renal Dysfunction in 94
Younger T2DM Patients
IRR 95% CI P Value
Baseline age 0.94 0.88–1.01 0.10
Male sex 1.25 0.89–1.61 0.18
Diabetes mellitus duration 1.00 0.97–1.03 0.99
Baseline eGFR 0.98 0.97–0.99 0.002
Albuminuria* 1.06 0.95–1.17 0.28
Ao-PWV 1.09 1.01–1.17 0.02
Hypertension 0.52 0.24–1.13 0.10
Glycated hemoglobin 1.005 0.99–1.02 0.39
No. of eGFR measurements 0.99 0.94–1.03 0.54
Final age at follow-up 1.05 0.99–1.12 0.10
Pulse pressure 1.00 0.98–1.01 0.90
Aortic pulse wave velocity (Ao-PWV) remained signiﬁcant predictor progression renal
dysfunction if systolic blood pressure or mean arterial pressure were entered in place of
pulse pressure and if renin-angiotensin-aldosterone inhibitors were entered in place of
hypertension. eGFR indicates estimated glomerular ﬁltration rate; IRR, incident rate ratio;
T2DM, type 2 diabetes mellitus.
*log albumin to creatinine ratio mg/mmol.
Table 5. Unadjusted and Adjusted Models Evaluating the
Effect of Ao-PWV on Progression of Renal Dysfunction in 94
Younger T2DM Patients
IRR 95% CI P Value
Unadjusted model 1.12 1.05–1.18 <0.001
Model 1 adjusted for age and sex 1.12 1.05–1.19 0.001
Model 2 adjusted for age, sex,
and baseline eGFR
1.12 1.05–1.19 0.001
Model 3 adjusted for age, sex,
baseline eGFR,
pulse pressure, ACR
1.08 1.01–1.16 0.028
Model 4 (model 3+diabetes mellitus
duration, glycated hemoglobin,
hypertension, number of eGFR
measurements, final age)
1.09 1.01–1.17 0.020
ACR indicates albumin to creatinine ratio; Ao-PWV, aortic pulse wave velocity; eGFR,
estimated glomerular ﬁltration rate; IRR, incident rate ratio; T2DM, type 2 diabetes
mellitus.
Table 6. Results of Repeated Measures Linear Mixed Model
Evaluating the Independent Variables That Predicted
Longitudinal Change in eGFR During Follow-Up in 94 Younger
T2DM Patients
Estimate 95% CI P Value
Age 0.001 0.74 to 0.75 0.99
Male sex 1.92 6.47 to 10.30 0.88
Diabetes mellitus duration 0.64 1.53 to 0.25 0.22
Baseline eGFR 0.84 0.57 to 1.10 0.001
Albuminuria* 0.18 2.53 to 2.89 0.89
Ao-PWV 2.1 4.10 to 0.09 0.04
Hypertension 14.3 29.05 to 0.35 0.06
Glycated hemoglobin 0.001 0.32 to 0.22 0.72
Pulse pressure 0.10 0.24 to 0.44 0.55
Ao-PWV remained signiﬁcant predictor progression renal dysfunction if systolic blood
pressure or mean arterial pressure were entered in place of pulse pressure and if renin
angiotensin aldosterone inhibitors were entered in place of hypertension. Ao-PWV
indicates aortic pulse wave velocity; eGFR, estimated glomerular ﬁltration rate; T2DM,
type 2 diabetes mellitus.
*log albumin to creatinine ratio mg/mmol.
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There were 47 deaths during follow-up (39 above and 8
below 60 years of age). Baseline Ao-PWV was not signiﬁcantly
different between patients who survived compared with those
who died (12.02.5 versus 11.72.7 m/s, P=0.47).
In patients older than 60 years, there were 22 deaths in the
progressor group and 17 deaths in the nonprogressor group.
The 8 deaths in patients younger than 60 were distributed
equally between progressors and nonprogressors and when
entered in analyses did not alter the signiﬁcant independent
effect of Ao-PWV on predicting renal disease progression.
Discussion
In this prospective study of T2DM patients with relatively
preserved renal function (eGFR >45 mL/min) we have
demonstrated that Ao-PWV is an independent predictor of
signiﬁcant progression of renal function decline in younger
patients aged below 60 years. Moreover, this effect of
Ao-PWV on eGFR decline was independent of BP variables
such as mean arterial pressure, pulse pressure, systolic BP,
and number of antihypertensive agents.
Recent studies in patients with T2DM suggest that the
average annual decline of renal function is <1 mL/min.13,14 In
our study, patients with progression had an annual mean
eGFR decline of 3.5 mL/min per year. Our results indicate
that an increase in Ao-PWV of 1 m/s increased the risk of
faster progression of renal function decline by a moderate 9%
in younger T2DM patients independent of other established
risk factors. In a repeated measures mixed model, we also
demonstrated that a 1-m/s increase in Ao-PWV is a
signiﬁcant predictor of a mean fall in eGFR of 2.1 (95% CI,
0.09–4.1) mL/min per year independent of established risk
factors only in younger patients. The results of net reclassi-
ﬁcation improvement analyses demonstrate that including Ao-
PWV in the model correctly reclassiﬁed a further 9% of the
“young” progressors compared with a model without Ao-PWV.
In contrast, in older patients, Ao-PWV did not predict faster
progression of eGFR decline. Age, which is signiﬁcantly
associated with Ao-PWV and the natural rate of eGFR decline,
may have confounded the relationship between Ao-PWV and
progression of renal disease.
We can speculate that in older patients with long-duration
diabetes mellitus, Ao-PWV may not add any predictive value as
aging per se strongly inﬂuences the determinants of arterial
stiffness (Ao-PWV was signiﬁcantly higher in older patients
compared with younger patients). This group of patients may
also have other factors driving renal disease progression such
as hypertensive and aging related renal disease.4,23 Younger
T2DM patients had a faster rate of fall in eGFR and this may
have contributed to Ao-PWV being a more sensitive predictor of
progression. T2DM patients of young age have accelerated
progression of renal dysfunction, often in the setting of a
proinﬂammatory milieu, insulin resistance, and obesity, which
are also known factors associated with increased Ao-PWV.24–26
Several studies have explored and reported discrepant
results on the predictive role of Ao-PWV and eGFR decline,
which may be due to the differing populations and disease
states evaluated.
Tomiyama et al reported that baseline brachial ankle pulse
wave velocity was related to a higher annual rate of decline in
eGFR in a cohort of 2053 (all younger than 47 years and <1%
with T2DM) Japanese employees with eGFR >60 mL/min.27 In
a prospective study of 133 patients with CKD stages 3 and 4
(only 6% had diabetes mellitus) followed for a mean of
1.5 years, Ao-PWV was independently associated with the
rate of decline of renal function.3 Bouchi et al28 studied 461
T2DM Japanese patients aged between 20 and 80 years, who
were admitted to the hospital for diabetes mellitus care, with
eGFR >15 mL/min, followed for a median duration of
5.9 years. The authors reported a signiﬁcant association of
Ao-PWV with the annual rate of eGFR decline in patients older
than 60 years and progression from normoalbuminuria to
microalbuminuria and microalbuminuria to macroalbuminuria.
However, only 30% of patients were on renin-angiotensin-
aldosterone system blockade at baseline (this increased to 55%
at the end of the study), the prevalence of diabetic retinopathy
was low (20.4%), and nondiabetic causes of renal disease were
not excluded, all of which could have inﬂuenced the results.28 A
recent general population study of older patients (mean age,
75 years and <10% with T2DM) followed for 5 years, Ao-PWV
predicted eGFR decline but not albuminuria.29
In contrast, a study in 2129 patients (mean age, 74 years and
14% with T2DM) demonstrated that rate of GFR fall was not
predicted by Ao-PWV.30 Similarly a general population study of
predominantly older patients (mean age, >60 years) withmild to
moderate CKD at baseline did not show an association between
baseline Ao-PWV measures and incident CKD over 7 to
10 years.31 In a 4-year prospective study of 27 newly diagnosed
treatment-naive T2DM patients (mean age, 60 years) and 47
patients with essential hypertension not on treatment, Ao-PWV
did not predict eGFR decline (deﬁned as fall >1 mL/min per
year) in T2DMpatients but did in patientswith hypertension only.
We studied a T2DM clinic cohort of predominantly Cau-
casian origin with less advanced kidney disease and longer
duration of diabetes mellitus who were followed for a longer
duration than those in many of the studies reported above. We
also excluded patients with nondiabetic renal disease.
Study Strengths
The strengths of our study are the long follow-up, the high
ascertainment rate (100%), and the standardized clinical care
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and measurements at a single center for the duration of the
follow-up. The median duration of follow-up was 9 years, with
a range from 3 to 11 years, and there were no differences in
follow-up time between patients with and without progression
of renal dysfunction. Our data from an outpatient clinical
cohort also reﬂects the heterogonous and changing nature of
the natural progression of renal dysfunction in patients with
T2DM where a signiﬁcant proportion of patients do not
display clinically meaningful reduction in renal function.13,14,32
We did not observe a statistically signiﬁcant independent
predictive effect of albuminuria as a continuous or categorical
risk marker for predicting progression of renal function
decline. A signiﬁcant proportion of our cohort had normal or
modestly raised urinary albumin excretion at baseline, and
there was a relatively high background use of renin-
angiotensin-aldosterone system inhibitors, which may explain
the above ﬁnding.
Study Limitations
There are several limitations to our study. The creatinine-
based eGFR equations may not be reliable and accurate for
GFR values >60 mL/min; however, the Chronic Kidney
Disease Epidemiology Collaboration equation that we used
is what is currently widely recommended in clinical practice.
More importantly, we measured sequential change in eGFR
over a long period of follow-up, which is more accurate in the
context of predicting risk of renal function decline.32,33 We
also did not take direct measurements of the mechanical
properties of the vessel wall. This would require an invasive
technique not applicable in such a clinical study. Our study
included a signiﬁcant percentage of patients of Afro-
Caribbean origin, which reﬂects our local population. Ethnicity
may affect Ao-PWV and renal disease progression.4,25 How-
ever, we did not observe a signiﬁcant effect of ethnicity on
progression of renal dysfunction. Finally, the number of
patients we studied is relatively small and our results need to
be conﬁrmed in larger cohorts. Our previous work and that of
others indicate that reduction in Ao-PWV may be achievable
with speciﬁc drug treatments.34 Although no clinical trial to
date has demonstrated that differential lowering of Ao-PWV
results in improved renal outcomes, our work establishes a
platform to address this important question in future clinical
studies. The importance of the need for such studies is
underscored by the epidemiological evidence that Ao-PWV per
se is an independent risk factor for progression of renal
disease.2,4
T2DM patients with a faster rate of progression will
develop the advanced stages of renal dysfunction and “hard”
renal end points and cardiovascular outcomes faster.24,35
Moreover, there is evidence that interventions that slow the
rate of decline of renal function in early phases of CKD may be
associated with longer-term cardiorenal protection.23,35 We
demonstrate that relatively early in the course of their renal
dysfunction, Ao-PWV may identify those at higher risk of
progression. Further conﬁrmatory studies are required to
establish whether Ao-PWV can help risk stratify and identify
patients at high risk for progression to advanced renal
disease.
Perspectives
Ao-PWV inouropinion represents the integratedeffect over time
of various factors on the arterial wall and provides a “long-term”
index of vascular aging analogous to a “long-term HbA1c.”
Intensive glycemic control implemented early in “relatively
younger” patients with a shorter duration of diabetes mellitus
results in a glycemic legacy effect of reducing diabetic compli-
cations including renal disease progression.36,37 Our data
suggest that in “younger patients” (<60 years) with T2DM,
there is a potential window of opportunity to intervene and
inﬂuence arterial aging that may delay progression of renal
dysfunction. This may not be the case in older patients with a
longer duration of disease and more advanced renal disease
where a J-shaped curve for pulse pressure reduction and clinical
outcomes is often observed.38 Younger T2DM patients have
fasterprogressionofcardiorenaldiseaseoftendrivenbyobesity-
associated increased insulin resistance.24,26,39–41 In our study,
younger patients with T2DM had shorter duration of diabetes
mellitus andgreater bodymass index,which, inpart,mayexplain
the above differences.26,39–41 However, this hypothesis needs
to be evaluated and conﬁrmed in further larger studies.
Conclusions
The results of our study demonstrate that an increased
Ao-PWV predicts progression of renal dysfunction indepen-
dent of traditional markers of renal risk in younger T2DM
patients below the age of 60 years. Our study establishes the
rationale and platform to evaluate in further studies whether
Ao-PWV is a potential target for renoprotection in T2DM.
Disclosures
None.
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